Stock Scorecard



Stock Summary for Biomea Fusion Inc (BMEA) - $1.84 as of 10/8/2025 3:48:52 PM EST

Total Score

11 out of 30

Safety Score

26 out of 100

Currently on the following lists
None
Tim's Recommendation
Avoid

Growth List Algorithm Criteria for BMEA

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for BMEA

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for BMEA

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for BMEA

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for BMEA (26 out of 100)

Stock Price Rating (Max of 10) 2
Historical Stock Price Rating (Max of 10) 4
Stock Price Trend (Max of 10) 1
Book Value (Max of 10) 1
Book Value to Price (Max of 10) 0
Analyst Buy Ratings (Max of 5) 4
Analyst Strong Buy Ratings (Max of 5) 4
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 0
Trading Volume (Max of 10) 10
Price to Earnings (Max of 10) 0
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Latest News for for BMEA

Biomea Fusion Plummets After Public Offering, Diabetes Study - Biomea Fusion ( NASDAQ:BMEA ) 10/7/2025 2:35:00 PM
Dow Jumps Over 100 Points; McCormick Earnings Top Views - Biomea Fusion ( NASDAQ:BMEA ) , EPWK Holdings ( NASDAQ:EPWK ) 10/7/2025 2:20:00 PM
Biomea Fusion Announces Proposed Public Offering of Securities - Biomea Fusion ( NASDAQ:BMEA ) 10/6/2025 8:18:00 PM
Biomea Fusion Announces Proposed Public Offering of Securities 10/6/2025 8:18:00 PM
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635 ( c ) ( 4 ) 10/1/2025 11:00:00 AM
Biomea Fusion Presents Data Demonstrating Enhanced Preclinical Activity of Icovamenib in Combination with Semaglutide in Type 2 Diabetes ( T2D ) Animal Model at the 61st EASD Annual Meeting and Provides Additional Corporate Update - Biomea Fusion ( NASDAQ:BMEA ) 9/16/2025 11:00:00 AM
This Oddity Tech Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - CoreWeave ( NASDAQ:CRWV ) , Biomea Fusion ( NASDAQ:BMEA ) 8/28/2025 12:43:00 PM
Biomea Fusion ( BMEA ) Q2 Loss Drops 44% 8/6/2025 2:21:00 AM
Biomea Fusion Appoints Julianne Averill to its Board of Directors - Biomea Fusion ( NASDAQ:BMEA ) 7/24/2025 11:00:00 AM
Biomea Fusion Presents New Preclinical and Clinical Data on Icovamenib at the 85th Scientific Sessions of the American Diabetes Association ( ADA ) - Biomea Fusion ( NASDAQ:BMEA ) 6/23/2025 11:00:00 AM

Financial Details for BMEA

Company Overview

Ticker BMEA
Company Name Biomea Fusion Inc
Country USA
Description Biomea Fusion Inc. is a pioneering biopharmaceutical company based in Redwood City, California, dedicated to the discovery and development of innovative irreversible small molecules aimed at treating genetically defined cancers. Leveraging cutting-edge science and a robust pipeline, Biomea is committed to addressing the unmet medical needs of patients with specific genetic mutations, thereby positioning itself at the forefront of targeted cancer therapies. With a strong focus on commercialization and a commitment to advancing patient care, Biomea is poised to significantly impact the oncology landscape.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 6/30/2025
Next Earnings Date 11/4/2025

Stock Price History

Last Day Price 1.84
Price 4 Years Ago 7.45
Last Day Price Updated 10/8/2025 3:48:52 PM EST
Last Day Volume 21,514,954
Average Daily Volume 1,038,801
52-Week High 13.07
52-Week Low 1.29
Last Price to 52 Week Low 42.64%

Valuation Measures

Trailing PE N/A
Industry PE 22.22
Sector PE 41.70
5-Year Average PE -2.80
Free Cash Flow Ratio 1.96
Industry Free Cash Flow Ratio 14.45
Sector Free Cash Flow Ratio 30.25
Current Ratio Most Recent Quarter 3.68
Total Cash Per Share 0.94
Book Value Per Share Most Recent Quarter 0.47
Price to Book Ratio 4.61
Industry Price to Book Ratio 29.58
Sector Price to Book Ratio 32.02
Price to Sales Ratio Twelve Trailing Months 0.00
Industry Price to Sales Ratio Twelve Trailing Months 44.16
Sector Price to Sales Ratio Twelve Trailing Months 20.22
Analyst Buy Ratings 4
Analyst Strong Buy Ratings 2

Share Statistics

Total Shares Outstanding 59,509,000
Market Capitalization 109,496,560
Institutional Ownership 48.39%

Dividends

Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement

Quarterly Earnings Growth YOY 0.00%
Annual Earnings Growth -18.06%
Reported EPS 12 Trailing Months -3.00
Reported EPS Past Year -1.31
Reported EPS Prior Year -3.84
Net Income Twelve Trailing Months -112,091,000
Net Income Past Year -138,426,000
Net Income Prior Year -117,255,000
Quarterly Revenue Growth YOY 0.00%
5-Year Revenue Growth 0.00%
Operating Margin Twelve Trailing Months 0.00%

Balance Sheet

Total Cash Most Recent Quarter 56,224,000
Total Cash Past Year 58,279,000
Total Cash Prior Year 176,866,000
Net Cash Position Most Recent Quarter 56,224,000
Net Cash Position Past Year 58,279,000
Long Term Debt Past Year 0
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 0
Equity to Debt Ratio Past Year 1.00
Equity to Debt Ratio Most Recent Quarter 1.00
Total Stockholder Equity Past Year 51,573,000
Total Stockholder Equity Prior Year 169,237,000
Total Stockholder Equity Most Recent Quarter 27,510,000

Free Cash Flow

Free Cash Flow Twelve Trailing Months -100,368,000
Free Cash Flow Per Share Twelve Trailing Months -1.69
Free Cash Flow Past Year -120,256,000
Free Cash Flow Prior Year -99,962,000

Options

Put/Call Ratio 0.06
Has Options Options Chain
Liquidity Rating

Technical Analysis

Yahoo Finance Chart Yahoo Finance Chart
MACD 0.07
MACD Signal 0.06
20-Day Bollinger Lower Band 1.33
20-Day Bollinger Middle Band 1.93
20-Day Bollinger Upper Band 2.53
Beta -0.14
RSI 61.73
50-Day SMA 3.30
150-Day SMA 10.87
200-Day SMA 10.21

System

Modified 10/7/2025 7:08:15 PM EST